Physical Activity Intervention for Older Patients During Chemotherapy for Colorectal Cancer

Not Applicable

Completed

• Conditions: Fatigue; Colorectal Cancer
• Interventions: Behavioral: Walk With Ease

• Registration Number: NCT02191969
• Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Brief Summary

This study will see if patient who undergo a physical activity intervention called Walk With Ease report experiencing less fatigue and a higher quality of life during chemotherapy for colorectal cancer than those who do not participate in this intervention.

Detailed Description

The primary purpose of this multicenter, randomized controlled study is to evaluate the impact of a physical activity program on fatigue in older patients (≥60 years) undergoing adjuvant chemotherapy for colorectal cancer. The investigators also plan to evaluate physical function and quality of life as secondary objectives. The investigators' hypotheses are that people who undergo the physical activity intervention compared to those who do not, will: 1) report less fatigue, 2) report higher health related quality of life, and 3) have less decline in physical function. Additionally, The investigators will characterize ≥grade 3 adjuvant chemotherapy associated toxicities in this older population, and describe the changes reported in fatigue, physical function, and HRQOL over the course of chemotherapy.

Study Timeline

• Study Start: 2014-06
• Study First Submitted: 2014-06-17
• Study First Submitted QC: 2014-07-14
• Study First Posted: 2014-07-16
• Primary Completion: 2019-09-18
• Study Completion: 2019-09-18
• Status Verified: 2019-11
• Last Update Submitted: 2020-04-29
• Last Update Posted: 2020-05-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• ≥ Age 60 years (no upper age limit)
• Diagnosis of stage II-III colon or rectal cancer planned for treatment with adjuvant chemotherapy scheduled as part of standard treatment
• Able to read English (required for CGA and other surveys administered)
• Approval from their treating physician to engage in moderate-intensity physical activity
• Patient-assessed ability to walk and engage in moderate physical activity
• Signed, IRB-approved written informed consent

Exclusion Criteria

• Other active, invasive malignancy requiring ongoing therapy or expected to require systemic therapy
• Already walking or engaging in other physical activity >120 minutes per week as documented via subject self-report
• Unable to walk or engage in moderate-intensity physical activity
• One or more significant medical conditions that in the physician's judgment preclude participation in the walking intervention

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Intervention	Walk With Ease	This group will be receiving adjuvant chemotherapy for colorectal cancer. They will participate in the Walk With Ease (WWE) program during the course of their chemotherapy treatment. They will be requested to initiate the WWE starting on Day 1 of adjuvant chemotherapy. Participants are asked to walk at a safe and comfortable pace, increasing their minutes per day at a rate they can sustain, with the ultimate goal of 30 minutes/day for at least 5 days/week. They are asked to maintain a daily walking log that is provided to them, entering total minutes per day. Participants will be asked to do the walking program independently (self-directed, not in a formal group with an instructor) throughout chemotherapy.

Primary Outcome Measures

Name	Time	Method
To measure the change in fatigue after three months between the intervention and control arm	Three Months	The investigators will compare the change in fatigue from baseline to 3 months between Intervention and Control arms as measured via PROMIS®-Fatigue.

Secondary Outcome Measures

Name	Time	Method
To measure the association of p16INK4a and muscle mass with any differences in fatigue o physical function or QOL during chemotherapy	Six months	To explore the association of baseline measurements of p16INK4a and muscle mass with changes in fatigue, physical function, and health related quality of life during adjuvant chemotherapy.
To measure changes in physical function at baseline between the intervention and control groups.	4 to 24 weeks	To evaluate the following measures at baseline, 3 months, and after completion of chemotherapy and compare changes in these measures over time between Intervention and Control arms.; • Physical function as measured by PROMIS-PF and SPPB
To measure adherence to the physical activity intervention	One Year	To report on the adherence of the physical activity intervention as measured through self-reported minutes of walking per days and walking minutes per week in the group randomized to the Intervention arm
To measure changes in ADLs at baseline between the intervention and control groups.	4 to 24 weeks	To evaluate the following measures at baseline, 3 months, and after completion of chemotherapy and compare changes in these measures over time between Intervention and Control arms.; ADLs per CGA
To measure changes in Instrumental Activities of Daily Living at baseline between the intervention and control groups.	4 to 24 weeks	To evaluate the following measures at baseline, 3 months, and after completion of chemotherapy and compare changes in these measures over time between Intervention and Control arms.; IADLs per CGA
To measure the difference in p16INK4a levels before and after chemotherapy in the control and intervention groups	One Year	The investigators will comparee the change in p16INK4a and muscle mass measurements pre/post adjuvant chemotherapy between Intervention and Control groups
To measure the change in muscle mass measurements before and after chemotherapy between the intervention and control arms	One Year	The investigators will compare the change in p16INK4a and muscle mass measurements pre/post adjuvant chemotherapy between Intervention and Control groups
To measure changes in Quality of Life at baseline between the intervention and control groups.	4 to 24 weeks	To evaluate the following measures at baseline, 3 months, and after completion of chemotherapy and compare changes in these measures over time between Intervention and Control arms.; Quality of life as measured by FACT-FCSI and PROMIS-PI
To measure changes in Self-Efficacy at baseline between the intervention and control groups.	4 to 24 weeks	To evaluate the following measures at baseline, 3 months, and after completion of chemotherapy and compare changes in these measures over time between Intervention and Control arms.; Self-efficacy and attitudes as measured by PSEFSM and OEE

Trial Locations

Locations (1)

University of North Carolina at Chapel Hill; 🇺🇸 Chapel Hill, North Carolina, United States